Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation

Transplantation

Volumn 84, Issue 7, 2007, Pages 814-820

  Fuji, Shigeo ^a   Kim, Sung Won ^a   Mori, Shin Ichiro ^a   Fukuda, Takahiro ^a   Kamiya, Shigemi ^a   Yamasaki, Satoshi ^a   Morita Hoshi, Yuriko ^a   Ohara Waki, Fusako ^a   Honda, Osamu ^b   Kuwahara, Setsuko ^a   Tanosaki, Ryuji ^a   Heike, Yuji ^a   Tobinai, Kensei ^a   Takaue, Yoichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Tokyo Anesthesiology Group   (Japan)

Author keywords

Acute graft versus host disease; Allogeneic transplantation; Hyperglycemia; Nonrelapse mortality

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; BUSULFAN; CEFEPIME; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUCONAZOLE; HYDROCORTISONE; METHOTREXATE; SULFAMETHOXAZOLE; TACROLIMUS; VANCOMYCIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; HERPES SIMPLEX VIRUS; HUMAN; HYPERGLYCEMIA; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SURVIVAL; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; ALLOTRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; NEUTROPENIA;

ADULT; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUTROPENIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 38449112256     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000296482.50994.1c     Document Type: Article

References (37)

1. Van den Berghe G, Wouters P, Weekwrs F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359.
2. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449.
3. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31: 359.
4. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78: 1471.
5. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79: 992.
6. Vogelzang M, Nijboer JM, van der Horst IC, et al. Hyperglycemia has a stronger relation with outcome in trauma patients than in other critically ill patients. J Trauma 2006; 60: 873.
7. Ingels C, Debaveye Y, Milants I, et al. Strict blood glucose control with insulin during intensive care after cardiac surgery: Impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 2006; 27: 2716.
8. Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145: 4084.
9. Brix-Christensen V, Andersen SK, Andersen R, et al. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: An experimental study in a porcine model. Anesthesiology 2004; 100: 861.
10. Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 656.
11. Sheean PM, Braunschweig C, Rich E. The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parenteral nutrition: A pilot study. J Am Diet Assoc 2004; 104: 1352.
12. Fietsam R Jr., Bassett J, Glover JL. Complications of coronary artery surgery in diabetic patients. Am Surg 1991; 57: 551.
13. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidney. J Invest Med 1997; 45: 50.
14. Vanhorebeek I, De Vos R, Mesotten D, et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005; 365: 53.
15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825.
16. Cavallo MG, Pozzilli P, Bird C, et al. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol 1991; 86: 256.
17. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996; 45: 954.
18. Borst SE. The role of TNF-alpha in insulin resistance. Endocrine 2004; 23: 177.
19. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002; 106: 2067.
20. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854.
21. Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82: 4167.
22. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3.
23. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181.
24. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575.
25. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629.
26. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101: 2440.
27. Krenger W, Ferrara JL. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996; 5: 3.
28. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181.
29. Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: A nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331.
30. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303.
31. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
32. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578.
33. Woo M, Przepiorka D, Ippoliti C, et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 1997; 20: 1095.
34. Margreiter R; European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741.
35. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062.
36. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157.
37. Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 94.